BACKGROUND AND PURPOSE: Motor speech alterations are a prominent feature of clinically manifest Huntington's disease (HD). Objective acoustic analysis of speech can quantify speech alterations. It is currently unknown, however, at what stage of HD speech alterations can be reliably detected. We aimed to explore the patterns and extent of speech alterations using objective acoustic analysis in HD and to assess correlations with both rater-assessed phenotypical features and biological determinants of HD. METHODS: Speech samples were acquired from 44 premanifest (29 pre-symptomatic and 15 prodromal) and 25 manifest HD gene expansion carriers, and 25 matched healthy controls. A quantitative automated acoustic analysis of 10 speech dimensions was performed. RESULTS: Automated speech analysis allowed us to differentiate between participants with HD and controls, with areas under the curve of 0.74 for pre-symptomatic, 0.92 for prodromal, and 0.97 for manifest stages. In addition to irregular alternating motion rates and prolonged pauses seen only in manifest HD, both prodromal and manifest HD displayed slowed articulation rate, slowed alternating motion rates, increased loudness variability, and unstable steady-state position of articulators. In participants with premanifest HD, speech alteration severity was associated with cognitive slowing (r = -0.52, p < 0.001) and the extent of bradykinesia (r = 0.43, p = 0.004). Speech alterations correlated with a measure of exposure to mutant gene products (CAG-age-product score; r = 0.60, p < 0.001). CONCLUSION: Speech abnormalities in HD are associated with other motor and cognitive deficits and are measurable already in premanifest stages of HD. Therefore, automated speech analysis might represent a quantitative HD biomarker with potential for assessing disease progression.

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Prague Czech Republic

Department of Neurology and ARTORG Center Inselspital Bern University Hospital University of Bern Bern Switzerland

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Neurology University Ulm Ulm Germany

Department of Neuropsychiatry Huntington Center South kbo Isar Amper Klinikum Taufkirchen Taufkirchen Germany

Zobrazit více v PubMed

Macdonald M. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-983. doi:10.1016/0092-8674(93)90585-E

Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1(1):10. doi:10.1038/nrdp.2015.5

Ross CA, Reilmann R, Cardoso F, et al. Movement disorder society task force viewpoint: Huntington's disease diagnostic categories. Mov Disord Clin Pract. 2019;6(7):541-546. doi:10.1002/mdc3.12808

Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, et al. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022;21(7):645-658. doi:10.1016/S1474-4422(22)00121-1

Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791-801. doi:10.1016/S1474-4422(09)70170-X

Scahill RI, Zeun P, Osborne-Crowley K, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease young adult study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 2020;19(6):502-512. doi:10.1016/S1474-4422(20)30143-5

Duffy JR. Motor Speech Disorders: Substrates, Differential Diagnosis and Management. 4th ed. Mosby; 2019.

Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J Speech Hear Res. 1969;12(2):246-269. doi:10.1044/jshr.1202.246

Diehl SK, Mefferd AS, Lin Y-C, et al. Motor speech patterns in Huntington disease. Neurology. 2019;93(22):2042-2052. doi:10.1212/WNL.0000000000008541

Velasco García MJ, Cobeta I, Martín G, Alonso-Navarro H, Jimenez-Jimenez FJ, Jimenez-Jimenez FJ. Acoustic analysis of voice in Huntington's disease patients. J Voice. 2011;25(2):208-217. doi:10.1016/j.jvoice.2009.08.007

Rusz J, Klempíř J, Baborová E, et al. Objective acoustic quantification of phonatory dysfunction in Huntington's disease. PLoS ONE. 2013;8(6):e65881. doi:10.1371/journal.pone.0065881

Ramig LA. Acoustic analyses of phonation in patients with Huntington's disease. Ann Otol Rhinol Laryngol. 1986;95(3):288-293. doi:10.1177/000348948609500315

Kaploun LR, Saxman JH, Paula Wasserman A, Marder K. Acoustic analysis of voice and speech characteristics in presymptomatic gene carriers of Huntington's disease: biomarkers for preclinical sign onset?: biomarkers for preclinical sign onset? J Med Speech-Lang Pathol. 2011;19:49-63.

Skodda S, Schlegel U, Hoffmann R, Saft C. Impaired motor speech performance in Huntington's disease. J Neural Transm. 2014;121(4):399-407. doi:10.1007/s00702-013-1115-9

Rusz J, Klempíř J, Tykalová T, et al. Characteristics and occurrence of speech impairment in Huntington's disease: possible influence of antipsychotic medication. J Neural Transm. 2014;121(12):1529-1539. doi:10.1007/s00702-014-1229-8

Thompson PD, Berardelli A, Rothwell JC, et al. The coexistence of bradykinesia and chorea in huntington's disease and its implications for theories of basal ganglia control of movement. Brain. 1988;111(2):223-244. doi:10.1093/brain/111.2.223

Vogel AP, Shirbin C, Churchyard AJ, Stout JC. Speech acoustic markers of early stage and prodromal Huntington's disease: a marker of disease onset? Neuropsychologia. 2012;50(14):3273-3278. doi:10.1016/j.neuropsychologia.2012.09.011

Skodda S, Grönheit W, Lukas C, et al. Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology. 2016;86(14):1329-1335. doi:10.1212/WNL.0000000000002550

Chan J, Stout JC, Shirbin CA, Vogel AP. Listener detection of objectively validated acoustic features of speech in Huntington's disease. J Huntingtons Dis. 2022;11(1):71-79. doi:10.3233/JHD-210501

Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington's disease: the integrated staging system. Lancet Neurol. 2022;21(7):632-644. doi:10.1016/S1474-4422(22)00120-X

Kremer HPH, Hungtington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136-142. doi:10.1002/mds.870110204

Smith A. The symbol-digit modalities test: a neuropsychologic test of learning and other cerebral disorders. Learn Disord Special Child Pub. 1968;1968(3):8.

Warner JH, Long JD, Mills JA, et al. Standardizing the CAP score in Huntington's disease by predicting age-at-onset. J Huntington's Dis. 2022;11(2):153-171. doi:10.3233/JHD-210475

Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153(2):397-408. doi:10.1002/ajmg.b.30992

Rusz J, Tykalova T, Ramig LO, Tripoliti E. Guidelines for speech recording and acoustic analyses in Dysarthrias of movement disorders. Mov Disord. 2021;36(4):803-814. doi:10.1002/mds.28465

Rusz J, Saft C, Schlegel U, Hoffman R, Skodda S. Phonatory dysfunction as a preclinical symptom of Huntington disease. PLoS ONE. 2014;9(11):e113412. doi:10.1371/journal.pone.0113412

Hlavnička J. Automated analysis of speech disorders in neurodegenerative diseases. Ph.D. Thesis. Czech Technical University; 2018.

Hlavnička J, Čmejla R, Klempíř J, Růžička E, Rusz J. Acoustic tracking of pitch, modal, and subharmonic vibrations of vocal folds in Parkinson's disease and parkinsonism. IEEE. IEEE Access. 2019;7:150339-150354. doi:10.1109/ACCESS.2019.2945874

Hlavnička J, Čmejla R, Tykalová T, Šonka K, Růžička E, Rusz J. Automated analysis of connected speech reveals early biomarkers of Parkinson's disease in patients with rapid eye movement sleep behaviour disorder. Sci Rep. 2017;7(1):10. doi:10.1038/s41598-017-00047-5

Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6(4):284-290. doi:10.1037/1040-3590.6.4.284

Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-191. doi:10.3758/BF03193146

Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 2010;75(24):2150-2160. doi:10.1212/WNL.0b013e3182020123

Gordon AM, Quinn L, Ralf Reilmann A, Marder K. Coordination of prehensile forces during precision grip in Huntington's disease. Exp Neurol. 2000;163(1):136-148. doi:10.1006/exnr.2000.7348

Rao AK, Muratori L, Louis ED, Moskowitz CB, Karen A, Marder S. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord. 2008;23(8):1100-1107. doi:10.1002/mds.21987

Smith MA, Jason Brandt A, Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature. 2000;403(6769):544-549. doi:10.1038/35000576

Heim B, Peball M, Saft C, et al. Time will tell: decision making in premanifest and manifest Huntington's disease. Brain Behav. 2020;10(11):10. doi:10.1002/brb3.1843

Friedova L, Rusz J, Motyl J, et al. Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: a pilot study. J Clin Neurosci. 2019;65(65):28-33. doi:10.1016/j.jocn.2019.04.018

Illner V, Tykalová T, Novotný M, Klempíř J, Petr Dušek A, Rusz J. Toward automated articulation rate analysis via connected speech in Dysarthrias. J Speech Lang Hear Res. 2022;65(4):1386-1401. doi:10.1044/2021_JSLHR-21-00549

Rusz J, Vaneckova M, Benova B, et al. Brain volumetric correlates of dysarthria in multiple sclerosis. Brain Lang. 2019;194(194):58-64. doi:10.1016/j.bandl.2019.04.009

Wolf RC, Thomann PA, Sambataro F, et al. Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease. J Neurol. 2015;262(4):859-869. doi:10.1007/s00415-015-7642-6

Riad R, Lunven M, Titeux H, et al. Predicting clinical scores in Huntington's disease: a lightweight speech test. J Neurol. 2022;269(9):5008-5021. doi:10.1007/s00415-022-11148-1

Rusz J, Hlavnička J, Novotný M, et al. Speech biomarkers in rapid eye movement sleep behavior disorder and Parkinson disease. Ann Neurol. 2021;90(1):62-75. doi:10.1002/ana.26085

Digital speech biomarkers can measure acute effects of levodopa in Parkinson's disease

Unravelling head tremor mechanisms: insights from speech analysis in essential tremor and cervical dystonia

An automatic measure for speech intelligibility in dysarthrias-validation across multiple languages and neurological disorders